EME Funding Committee Minutes March 2023

Day 1

Date

Tuesday 28 February 2023

Place

DoubleTree by Hilton London Angel Kings Cross, 60 Pentonville Road, London, N1 9LA

Present

Professor Danny McAuley (Programme Director - does not vote)
Professor John Norrie (Programme Chair)
Professor Maya Buch (Deputy Chair)
Professor Victoria Allgar
Dr Alun Bedding - left at 3pm
Professor James Burton
Mr Paul Charlton (PPI)
Professor Vicky Coyle
Professor Daniel Freeman
Mrs Hayley Hall (PPI)
Professor George Hanna
Professor Dave Jones
Professor Patricia Limousin
Dr Ronan McMullan
Dr Puja Mehta
Dr Philip Pallmann
Professor Don Sharkey
Professor John Simpson
Professor Deborah Stocken
Professor Stuart Taylor
Professor Claire Surr - Co-optee
Dr Mike Clark - Co-optee 

Secretariat

Dr Andrew Cook
Dr Juliana Callaghan
Dr Elena Harden
Ms Helen Munday
Ms Caitlin van Abeelen

Apologies

Dr Tessa Cacciottolo
Professor Alastair Hay
Professor Andrew Horne
Professor Gregory Lip
Professor Manu Shankar-Hari
Penny Morton, MRC 

Observers/in attendance

Dr Rajna Golubic, new DCM
Dr Rob Forsyth, new DCM
Dr Sabina Hulbert, RDS

Stage 2 Proposals

22/43 Efficacy and Mechanism Evaluation Programme researcher-led

NIHR154749 - Hartley
IMPACT (‘IMplemented by Parents And Carers’ Therapy) trial: A multicentre randomised controlled trial to evaluate the efficacy of a parent-implemented therapy on language development in deaf children with cochlear implants, and the mechanisms by which this therapy exerts its effects.
Chair: John Norrie
Declared a conflict and left the room: Don Sharkey
Decision: Recommended to Programme Director to consider Fund with Changes

NIHR154840 - Fisher 
REmission induction of Arthritis caused by Cancer ImmunoTherapy (REACT): a randomised multicentre trial to guide initial therapy for checkpoint inhibitor (CPI) induced arthritis
Chair: John Norrie
Declared a conflict and left the room: David Jones, Deborah Stocken, Maya Buch, John Simpson
Decision: Recommended to Programme Director to consider Fund with Changes

NIHR153865 - Sturt
Efficacy and mechanisms evaluation of novel therapy vs waiting list control for Post-Traumatic Stress Disorder (PTSD) in UK military veterans
Chair: John Norrie
Declared a conflict and left the room: Danny McAuley
Decision: Decline - Invited to resubmit a Stage 2 application

21/609 Efficacy and Mechanism Evaluation Programme researcher-led

NIHR153014 - Griffith
INtravenous iron and eryThropoietin to treat Anaemia following CriTical care-2 (INTACT-2): a multi-centre, randomised, parallel group, double-blind, placebo-controlled, phase II efficacy trial with an embedded mechanistic evaluation
Chair: Maya Buch 
Declared a conflict and left the room: John Simpson, Ronan McMullan, John Norrie, Danny McAuley, Andrew Horne (not present), Philip Pallmann, Manu Shankar-Hari (not present), Rob Forsyth (observer)
Decision: Decline - Invited to resubmit a Stage 2 application

22/43 Efficacy and Mechanism Evaluation Programme researcher-led

NIHR154807 - Ayling
Bio-psychological Mechanisms of Action in Improving Diabetic Foot Ulcer Outcomes 
Chair: John Norrie
Declared a conflict and left the room: Alastair Hay (not present), Don Sharkey
Decision: Recommended to Programme Director to consider Fund with Changes

NIHR154842 - Ackland
GlucoVITAL: randomised controlled mechanistic substudy of the Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery (VITAL) trial [NIHR130573]
Chair: Maya Buch
Declared a conflict and left the room: Deborah Stocken, John Norrie, Danny McAuley
Decision: Recommended to Programme Director to consider Fund with Changes

NIHR153209 - Antcliffe
FLuid strategies and Inflammatory Phenotypes in the SepTIC trial (FLIP-SepTIC) 
Chair: Maya Buch
Declared a conflict and left the room: George Hanna, Stuart Taylor, John Simpson, Manu Shankar-Hari (not present), Vicky Coyle, Ronan McMullan, John Norrie, Danny McAuley
Decision: Recommended to Programme Director to Fund with Changes

Stage 1 Proposal

22/111 Mechanism of Action of Social Care Interventions

NIHR156888 - Fox
Understanding the mechanisms Social Prescribing for people with dementia: what works best, how much is necessary, and whether the type and quality of support influence outcomes
Chair: John Norrie
Declared a conflict and left the room: Andrew Cook
Decision: Decline

Day 2

Date

Wednesday 1 March 2023

Present - Day 2 

Professor Danny McAuley (Programme Director - does not vote)
Professor John Norrie (Programme Chair)
Professor Maya Buch (Deputy Chair)
Professor Victoria Allgar
Dr Alun Bedding
Professor James Burton
Mr Paul Charlton (PPI)
Professor Vicky Coyle
Professor Daniel Freeman
Mrs Hayley Hall (PPI)
Professor George Hanna
Professor Dave Jones
Professor Patricia Limousin
Dr Ronan McMullan
Dr Puja Mehta
Dr Philip Pallmann
Professor Manu Shankar-Hari
Professor Don Sharkey
Professor John Simpson
Professor Deborah Stocken - left at 11.30am
Professor Stuart Taylor 

Secretariat

Dr Andrew Cook - arrived at 10am
Dr Juliana Callaghan
Dr Elena Harden
Ms Helen Munday
Ms Caitlin van Abeelen

Apologies

Dr Tessa Cacciottolo
Professor Alastair Hay
Professor Andrew Horne
Professor Gregory Lip
Penny Morton, MRC 

Observers/In Attendance

Dr Rajna Golubic, new DCM
Dr Rob Forsyth, new DCM
Dr Oya Eddama, RDS 

Stage 1 Proposals

22/108 Pain management for children and young people (0-19 years)

NIHR156691 - Walker
NEUSTAC Trial: Neuropathic pain MechanismS and Treatments in Adolescents with Chronic Pain
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Shortlist

22/18 Applications with industry collaboration - The development and evaluation of predictive algorithms using Artificial Intelligence (AI) (EME Programme)

NIHR153320 - Bath
Validation of AI technology for estimating lesion volume and detecting large vessel occlusion in patients with acute ischaemic stroke: Prospective Real-world AI in Stroke Evaluation (PRAISE)
Chair: John Norrie
Declared a conflict and left the room: John Simpson, Don Sharkey
Decision: Decline

22/110 Efficacy and Mechanism Evaluation Programme researcher-led

NIHR156614 - El - Damanawi
Implementation of Metformin theraPy to Ease Decline of kidney function in Polycystic Kidney Disease (IMPEDE-PKD) Randomised Placebo-Controlled Trial
Chair: John Norrie
Declared a conflict and left the room: John Simpson
Decision: Shortlist

NIHR156651 - Kotecha
Bacterial mucosal immunotherapy for prevention of wheeze in preterm born infants (BALLOON Trial)
Chair: John Norrie
Declared a conflict and left the room: Alastair Hay (not present), Philip Pallmann, Rob Forsyth (observer), George Hanna
Decision: Shortlist

NIHR156736 - Myers
Postnatal enalapril to Improve Cardiovascular fUnction and remodelling following hypertensive disorders of Pregnancy 2
Chair: John Norrie
Declared a conflict and left the room: Daniel Freeman, Alastair Hay (not present)
Decision: Shortlist

NIHR156955 - Goodman
PET SNAP (The use of (18)FDG positron emission tomography with computed tomography (PET/CT) and whole-body MRI (WB-MRI) in Staphylococcus aureus bacteraemia/bloodstream infection through the international S. aureus network adaptive platform trial)
Chair: John Norrie
Declared a conflict and left the room: Philip Pallmann, Stuart Taylor
Decision: Decline

NIHR157350 - Travis
PANDORA: Proteomic biomArker profiliNg to preDict therapy respOnse: testing a pRedictive pAnel in patients with ulcerative colitis undergoing advanced therapy
Chair: John Norrie
Declared a conflict and left the room: Stuart Taylor, Puja Mehta
Decision: Decline

NIHR155871 - Pavlides
Evaluation of non-contrast enhanced magnetic resonance imaging compared to standard of care ultrasound as screening tests for hepatocellular cancer in patients with liver cirrhosis
Chair: John Norrie
Declared a conflict and left the room: Don Sharkey
Decision: Shortlist

NIHR156260 - Velayudhan
A Randomized, Double Blind, Placebo-controlled Study of CANnabidiol for psychosis in Alzheimer’s Dementia (CAN-AD)
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Decline

NIHR156381 - Heaney
Residual disease in myeloma: Evaluating a new highly sensitive, patient-friendly, serum-based methodology to enable measurement to be integrated into UK clinical practice
Chair: John Norrie
Declared a conflict and left the room: Deborah Stocken
Decision: Decline

NIHR156391 - Valdes
Mechanisms of Efficacy of Early Hip Fracture Surgery
Chair: John Norrie
Declared a conflict and left the room: Don Sharkey, James Burton
Decision: Decline

NIHR156271 - Thursz
Faecal Transplantation for Alcohol-Related Hepatitis
Chair: Maya Buch
Declared a conflict and left the room: John Simpson, Ronan McMullan, John Norrie, George Hanna
Decision: Shortlist

22/42 NIHR James Lind Alliance Priority Setting Partnerships rolling call (EME Programme: April 22 - August 22)

NIHR154244 - Crosbie
The Refining Adjuvant treatment IN endometrial cancer Based On molecular features (RAINBO) No Specific Molecular Profile (NSMP)-ORANGE Trial
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Shortlist

22/105 NIHR James Lind Alliance Priority Setting Partnerships rolling call (EME Programme: August 22 - December 22)

NIHR156766 - Savaridas
Monitoring response to neoadjuvant chemotherapy - contrast enhanced mammography versus magnetic reconsance imaging, a non-inferiority study
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Decline - invited to resubmit a Stage 1 application

NIHR156519 - Okines
Evaluation of the efficacy of whole-body magnetic resonance imaging with diffusion-weighted imaging (WBMRI) compared to standard imaging for the accurate characterisation and staging of early lobular breast cancer
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Decline

NIHR156754 - Pomeroy
Optimising efficacy of mirror movement therapy for improved recovery of ankle neuromuscular control after stroke: MMT-ankle Trial
Chair: John Norrie
Declared a conflict and left the room: N/A
Decision: Decline - invited to resubmit a Stage 1 application

NIHR156531 - Khoo
EqUATOR: Evaluating the Use of Ablative Therapy in addition to standard treatment for Oligometastatic disease in Renal cell carcinoma – a phase II randomised controlled trial
Chair: Maya Buch
Declared a conflict and left the room: John Norrie
Decision: Decline